Lisata clinches rare disease status for osteosarcoma drug
22 Mar 2024
Fast TrackOrphan DrugPhase 2
Preview
Source: Pharmaceutical Technology
The FDA granted Lisata Therapeutics a rare pediatric drug designation for osteosarcoma, a rare blood cancer. Credit: FatCamera via Getty Images.
The US Food and Drug Administration (FDA) has granted Lisata Therapeutics a rare pediatric disease designation (RPDD) for its osteosarcoma treatment, LSTA1 (certepetide).
Lisata’s lead candidate is a cyclic peptide that is designed to activate the CendR uptake pathway, leading to an improved uptake of co-administered drugs. The intravenous therapy also works as a neuropilin-1 (NRP1) antagonist that prevents tumour cell migration and adhesion.
Currently, the US-based biotech is investigating LSTA1 across six Phase I and Phase II studies. One of these is the Phase II BOLSTER study (NCT05712356), in which Lisata is investigating the therapy for the treatment of solid tumours. The multi-centre trial is enrolling participants and is expected to complete accrual by the end of 2024, as per a 29 February company update. In addition to studying LSTA1 in a basket solid tumour trial, Lisata is also exploring the therapy’s potential more specifically for colon and appendiceal cancers.
In June 2022, the FDA also rewarded the drug a fast-track designation for pancreatic cancer, which was later followed by a European Medicines Agency (EMA) orphan drug designation in the same indication in September 2023. The FDA also granted LSTA1 orphan status a month later. Due to the most recent designation for osteosarcoma, if the FDA later approves a new drug application for LSTA1 in the indication, the company will receive a priority review voucher.
In a 21 March press release announcing the rare pediatric drug designation, Dr Kristen Buck, Lisata’s Chief Medical Officer, said “LSTA1 has already demonstrated promise in preclinical and clinical settings for the treatment of several advanced solid tumours, and we believe that potential extends to a beneficial impact in osteosarcoma, a rare cancer that usually develops in the osteoblast cells that form bone.”
See Also:
Pharmaceutical drug delivery market and systems
Preview
Source: Pharmaceutical Technology
Ascendis Pharma files patent for ocular drug delivery system using cross-linked Ha
Preview
Source: Pharmaceutical Technology
The American Cancer Society reports that each year 100 new cases of osteosarcoma are diagnosed in the US, with approximately 50% of cases accounted for by children and teenagers. The organisation also found that osteosarcoma cases make up approximately 2% of childhood cancer cases.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.